Chimerix Dividends and Buybacks

Dividend criteria checks 0/6

Chimerix does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.2%

Buyback Yield

Total Shareholder Yield	-0.2%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%

Jan 08

Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Jan 01

Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure

Dec 07

Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Dec 05

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CMRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CMRX's dividend payments have been increasing.

Dividend Yield vs Market

Chimerix Dividend Yield vs Market

How does CMRX dividend yield compare to the market?
Segment	Dividend Yield
Company (CMRX)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.5%
Analyst forecast (CMRX) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate CMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CMRX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CMRX has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 09:52
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chimerix, Inc. is covered by 22 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Geoffrey Meacham	Barclays
Jonathan Aschoff	Brean Capital
Ritu Baral	Canaccord Genuity

Chimerix Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Chimerix, Inc. Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Chimerix, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 36%

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)

Price target decreased by 8.7% to US$7.00

Chimerix, Inc., Annual General Meeting, Jun 20, 2024

Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024

Chimerix Appoints Marc D. Kozin to Board of Directors

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Chimerix Announces Board Changes

Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer

Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer

Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer

Consensus revenue estimates fall by 22%

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)

Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery

Consensus revenue estimates decrease by 48%, EPS upgraded

New minor risk - Market cap size

Price target decreased by 8.3% to US$7.33

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023

Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index

CEO, President & Director recently bought US$98k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study

Price target decreased to US$8.00

Rubric Capital Management Sends Letter to Chimerix

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Price target decreased to US$8.00

Chief Business Officer exercised options to buy US$111k worth of stock.

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chimerix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Price target decreased to US$8.20

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Consensus EPS estimates fall by 23%

Consensus estimates of losses per share improve by 44%

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative Announces Late-Breaking Oral Presentation At International Conference on Antiviral Research

Chimerix, Inc. Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Chimerix: Searching For Clarity

Forecast to breakeven in 2024

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in 3Q 2020)

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Consensus revenue estimates fall to US$27.8m

Independent Director recently bought US$78k worth of stock

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

Consensus forecasts updated

Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox

Forecast to breakeven in 2024

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

Chimerix Investor Presentation - Slideshow